ReviewGenome biology2014
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.
Review in Genome biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
119 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The impact of intratumor heterogeneity on outcome and resistance to therapy in primary breast cancer: a systematic review.Medical oncology (Northwood, London, England) · 2026Pooled it
- Application value of different imaging methods in the early diagnosis of small hepatocellular carcinoma: a network meta-analysis.Frontiers in oncology · 2024Pooled it
- The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study.Targeted oncology · 2020Trial
- Tumor evolution: signaling pathways, molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Single-cell copy number alteration signature analysis reveals masked patterns and potential biomarkers for cancer.Communications biology · 2025Article
- Dissecting Tumor Heterogeneity by Liquid Biopsy-A Comparative Analysis of Post-Mortem Tissue and Pre-Mortem Liquid Biopsies in Solid Neoplasias.International journal of molecular sciences · 2025Article
- DNA repair and the contribution to chemotherapy resistance.Genome medicine · 2025Review
- Systematic data analysis pipeline for quantitative morphological cell phenotyping.Computational and structural biotechnology journal · 2024Review
- STARD7 could be an immunological and prognostic biomarker: from pan-cancer analysis to hepatocellular carcinoma validation.Discover oncology · 2024Article
- Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer.Scientific reports · 2024Article
- Imaging Genomics of Glioma Revisited: Analytic Methods to Understand Spatial and Temporal Heterogeneity.AJNR. American journal of neuroradiology · 2024Review
- Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal.The oncologist · 2024Article
- The reckoning of chromosomal instability: past, present, future.Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology · 2024Review
- Article
- Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.ACS pharmacology & translational science · 2023Review
- ConDoR: tumor phylogeny inference with a copy-number constrained mutation loss model.Genome biology · 2023Article
- Spatial mapping of tumor heterogeneity in whole-body PET-CT: a feasibility study.Biomedical engineering online · 2023Article
- Single-Cell Evolutionary Analysis Reveals Drivers of Plasticity and Mediators of Chemoresistance in Small Cell Lung Cancer.Molecular cancer research : MCR · 2023Article
- The nature of cancer.Frontiers of medicine · 2023Article
59 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The presence of multiple subclones within tumors mandates understanding of longitudinal and spatial subclonal dynamics. Resolving the spatial and temporal heterogeneity of subclones with cancer driver events may offer insight into therapy response, tumor evolutionary histories and clinical trial design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.